Aurobindo Pharma USA has cleared a key regulatory hurdle in its push to expand its US footprint, announcing it has received approval from the US Federal Trade Commission to move forward with its acquisition of Lannett Company.

 

The $250 million transaction—on a cash-free, debt-free basis and inclusive of normalized working capital—is expected to close before the end of June 2026.

 

Lannett, a Pennsylvania-based generic drugmaker, is known for its portfolio of complex, non-opioid controlled substances. The deal is set to significantly broaden Aurobindo USA’s offerings in this niche while adding a major U.S. manufacturing asset to its network.

 

At the center of the expansion is Lannett’s Seymour, Indiana facility, which can produce up to 4 billion doses annually. The site is expected to materially strengthen Aurobindo’s domestic manufacturing capacity at a time when U.S. policy continues to emphasize supply chain resilience and increased local pharmaceutical production.

 

Financially, the acquisition is projected to be immediately accretive to Aurobindo Group’s earnings per share. The company also expects meaningful cost efficiencies, SG&A synergies, and operational integration benefits, alongside a strengthened pipeline of complex generics designed to support long-term growth.

 

Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, said, “This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances. 

 

"We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion. We are pleased to welcome the Lannett team and look forward to leveraging our combined strengths to expand and ensure reliable access to critical medications for patients.”

 

Lannett CEO Tim Crew struck an equally optimistic tone, saying, “We are delighted to be joining forces with Aurobindo. As one of the nation’s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. 

 

"Aurobindo’s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere. Our board and owners extend their sincere appreciation to the outstanding teams at both companies whose professionalism, commitment, and hard work have successfully brought us to this important moment. We look forward to building on all that has come before as we begin a bright and exciting next chapter.”

 

The deal positions Aurobindo to deepen its presence in the U.S. generics market while expanding its manufacturing and controlled-substance capabilities in a single strategic move.